Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2013
Event: Entry into a Material Definitive Agreement for a registered direct offering of common stock.
Key Financial Metrics
This filing reports on a capital raise rather than operational financial performance. Specific metrics include:
- Shares Offered: 3,903,004 shares of common stock.
- Offering Price: $4.14 per share.
- Expected Net Proceeds: Approximately $16.1 million (after deducting offering expenses).
- Expected Closing Date: On or about May 14, 2013.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the execution of Subscription Agreements with affiliates of RA Capital Management and certain other investors. The offering is being conducted without an underwriter or placement agent. The shares are being offered pursuant to an effective shelf registration statement on Form S-3.
Use of Proceeds and Outlook
Management intends to use the net proceeds for general corporate purposes, specifically:
- Expenses related to the potential commercialization of OMS302 for intraocular lens replacement.
- Research and development expenses, including funding planned clinical trials for OMS103HP, PDE10, MASP-2, and PDE7 programs.
- Funding pre-clinical studies and capital expenditures.
- Working capital to advance potential products toward commercialization.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard nature of a capital raise and the development stage of the mentioned drug programs.
Investor Verification Checklist
- Verify the final closing date of the offering (expected May 14, 2013).
- Confirm the exact net proceeds received after all offering expenses are deducted.
- Review the specific terms of the Subscription Agreement (Exhibit 10.1) for any covenants or restrictions.
- Monitor subsequent filings for updates on the clinical trial progress for OMS103HP, PDE10, MASP-2, and PDE7.
- Check for any dilution impact on existing shareholders resulting from the issuance of 3,903,004 new shares.